RedHill Biopharma Ltd. (RDHL) Comparison with companies in other sectors?

RedHill Biopharma Ltd. has a share price of 2.30M. You can analyze RedHill Biopharma Ltd. (RDHL) competitors across different market sectors through stock heatmaps.

What are RDHL's NET and operating margins?

RedHill Biopharma Ltd. (RDHL) operating margin is around -1.82, and net profit margin is approximately -1.03 as of the latest reports.

In what way does RDHL's earnings per share (EPS) trend reflect its financial momentum?

RedHill Biopharma Ltd. (RDHL) EPS is -302.63 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for RedHill Biopharma Ltd. is -0.01, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for RedHill Biopharma Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for RedHill Biopharma Ltd. like P/E which is -0.68, P/B which is -1.21, and PEG which is -0.01. Compare them with sector averages to evaluate if the stock is priced fairly.

RedHill Biopharma Ltd.

RDHL•NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

$2.17

$-0.18(-7.66%)

Fundamental Analysis of RedHill Biopharma Ltd. (RDHL)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-302.63

P/E Ratio

-0.01

ROE

3.58%

Net Margin

-1.03%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$4.98M

Shares OutstandingTotal number of shares issued

$2.30M

Book Value/ShareNet worth per share

$-1.82

Revenue/ShareAnnual revenue per share

$3.12

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-302.63

Net MarginNet income as percentage of revenue

-102.80%

Operating MarginOperating income as percentage of revenue

-181.69%

ROEReturn on shareholders' equity

357.77%

ROAReturn on total assets

-45.82%

ROCEReturn on capital employed

349.59%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-3.64

Cash/ShareCash and equivalents per share

$1.79

FCF YieldFree cash flow as percentage of market cap

-187.34%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for RDHLFinancial Ratios Analysis details for RDHL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for RDHLSector Benchmarking details for RDHL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for RedHill Biopharma Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of RedHill Biopharma Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account RedHill Biopharma Ltd.'s unique business strengths and challenges.

Key Financial Metrics for RedHill Biopharma Ltd.

For RedHill Biopharma Ltd., essential financial indicators include EPS -302.63, PE -0.01, and ROE 3.58. These key ratios reveal insights into RedHill Biopharma Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare RedHill Biopharma Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of RedHill Biopharma Ltd.

Metrics like Net Margin -102.80% and ROA -45.82% shed light on how well RedHill Biopharma Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether RedHill Biopharma Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of RedHill Biopharma Ltd.

Using ratios such as P/B Ratio -1.21 and PEG Ratio -0.01, investors can assess whether RedHill Biopharma Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with RedHill Biopharma Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for RedHill Biopharma Ltd.

Financial health indicators, such as Debt/Equity Ratio -0.08 and Cash Flow $-3.64, provide a snapshot of RedHill Biopharma Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like RedHill Biopharma Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for RedHill Biopharma Ltd.

Investing in RedHill Biopharma Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at RedHill Biopharma Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;